Skip to main content
Evidence Snapshot

Platelet

CHEMBL4296519 CELL-LINE
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:52:47Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4296519
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Platelet as ChEMBL target CHEMBL4296519. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Platelet
CELL-LINE
As of 2026-09-13
ChEMBL target ID
CHEMBL4296519
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Platelet matters

As of 2026-09-13

Platelet is reviewed as Platelet; the current evidence base includes 11 approved drugs, 1500 compounds, and 499 assays, with lead potency reaching pChEMBL 9.7.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 11 approved drugs, 1500 compounds, and 499 assays for this target. The dominant activity type is IC50. CHEMBL2087703 is the current potency anchor at pChEMBL 9.7.

Use CHEMBL2087703 as the tractability anchor when discussing potency (pChEMBL 9.7).

Activity source · ChEMBL 36 via Core Engine
11 approved pChEMBL 9.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Platelet matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1500
Total Compounds
499
Total Assays
11
Approved Drugs
IC50: 1341.0, EC50: 6.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2087703
 9.7 IC50 —
No preferred name
CHEMBL539697
 9.5 IC50 Approved
No preferred name
CHEMBL1097279
 9.4 IC50 Approved
No preferred name
CHEMBL5593488
 8.7 IC50 —
No preferred name
CHEMBL603490
 8.7 IC50 —

Approved Drugs

Structure Compound First Approval
CANGRELOR TETRASODIUM
CHEMBL1097279
 2015
VORAPAXAR
CHEMBL493982
 2014
DABIGATRAN ETEXILATE
CHEMBL539697
 2008
TIROFIBAN
CHEMBL916
 1998
MOFEZOLAC
CHEMBL259972
 1994
TICLOPIDINE
CHEMBL833
 1991
INDOMETHACIN
CHEMBL6
 1965
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:52:47Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4296519